Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

Dual inhibition of HER2 in breast cancer treatment

(2012) Michael Gnant et al.   LANCET

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

(2012) Michael Untch et al.   LANCET ONCOLOGY

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

(2011) Allan Lipton et al.   CANCER

HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer

(2011) Chantal Tsé et al.   CANCER TREATMENT REVIEWS

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

(2011) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial

(2010) G. von Minckwitz et al.   ANNALS OF ONCOLOGY

Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

(2010) Isabell Witzel et al.   BREAST CANCER RESEARCH AND TREATMENT

Lapatinib for breast cancer: a review of the current literature

(2010) Robyn J MacFarlane et al.   Expert Opinion On Drug Safety

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

(2010) Alejandro Vazquez-Martin et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

(2010) Michael Untch et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study

(2009) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum HER-2/neuand relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

(2008) Suhail M. Ali et al.   CANCER